Activities of Marco CAMPOMENOSI related to 2020/2071(INI)
Opinions (1)
OPINION on shortage of medicines – how to address an emerging problem
Amendments (15)
Amendment 18 #
Draft opinion
Recital C a (new)
Recital C a (new)
C a. whereas stocks are often not in the right storage location, even if available in the supply chain, and patients are unable to get them at the delivery point due to a lack of information, giving a false sign of a shortage of medicines;
Amendment 30 #
Draft opinion
Paragraph 1
Paragraph 1
1. Calls on the Member States to enhance their cooperation in order to improve the distribution chain through better visibility and efficient monitoring, planning and timely exchange information regarding important deliveries, particularly on cross-border routes, and to establish corridors where medical supplies have priority of delivery;.
Amendment 46 #
Draft opinion
Paragraph 3
Paragraph 3
3. Calls on the Member States to adopt strategic plans to upgrade their existing infrastructure for an efficient supply of medicines, including inexpensive, essential medicines; deems it necessary to remove bottlenecks, boost intermodality (while favouring the shift to rail), finance the main hubs (ports, airports and intermodal platforms), and enhance the delivery of various types of goods, including dangerous goods crucial for the production of the chemical and pharmaceutical industry;
Amendment 82 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7 a. Stresses the need to reduce transport costs, while preserving the level of service, minimising the number of kilometres of the routes, having ready and effective response tools to changes, both in ordinary operations and in exceptional periods of crisis, such as for COVID-19;
Amendment 85 #
Draft opinion
Paragraph 7 b (new)
Paragraph 7 b (new)
7 b. Calls for the implementation of innovative solutions to enable the safe transport of temperature-sensitive drugs, tracing the products through a constant remote monitoring in real time of medicines and their temperature from production to the final customer;
Amendment 87 #
Draft opinion
Paragraph 7 c (new)
Paragraph 7 c (new)
7 c. Calls for a revision of the EU Guidelines on Good Distribution Practice (GDP) of medicinal products for human use, taking into account the need to improve the efficiency of the supply chain, to reduce the products losses, and to implement innovative solutions, also in light of the recent COVID-19 outbreak;
Amendment 90 #
Draft opinion
Paragraph 7 d (new)
Paragraph 7 d (new)
7 d. Calls on the Member States to implement strategies improving prevention and management of shortages caused by disruptions in the supply chain, to develop guidance for companies on reporting of shortages, and to favour the exchange of best practices among regulatory authorities to better coordinate actions between Member States;
Amendment 91 #
Draft opinion
Paragraph 7 e (new)
Paragraph 7 e (new)
7 e. Calls on the Commission to revise Directive 2008/68/EC on the inland transport of dangerous goods adopting specific measures for the supply of dangerous goods in support of the chemical and pharmaceutical industry;
Amendment 92 #
Draft opinion
Paragraph 7 f (new)
Paragraph 7 f (new)
7 f. Calls on the Commission to revise Directive 92/106/EEC on the establishment of common rules for certain types of combined transport of goods between Member States assessing possible provisions aimed at improving the logistics chain for the transport of medicines;
Amendment 93 #
Draft opinion
Paragraph 7 g (new)
Paragraph 7 g (new)
7 g. Calls on the Commission to address the problem of the shortage of medicines in the work programmes adopted within the Multi-Annual Financial Framework 2021-2027, in particular by increasing the focus on aspects linked to research and innovation under Horizon Europe and other programmes;
Amendment 94 #
7 h. Calls on the Commission to implement an observatory, monitoring and coordinating actions at European- level, about the shortages of medicines, without any increase of the EU's budget.
Amendment 95 #
Draft opinion
Paragraph 7 i (new)
Paragraph 7 i (new)
7 i. Calls on the Commission and Member States to closely coordinate to protect the resilience and sustainability of the healthcare supply chain, which ensures the continuous availability of medicines, as well as their safe distribution and fair allocation to all dispensing points within Member States.
Amendment 96 #
Draft opinion
Paragraph 7 j (new)
Paragraph 7 j (new)
7 j. Calls for transparency at EU level through the introduction of a Europe- wide medicines shortages database and an early warning system involving the main supply chain stakeholders, from manufacturers, full-service healthcare distributors / pharmaceutical full-line wholesalers, pharmacists to prescribers and the national competent authorities, about existing and anticipated shortages, providing their root causes in a harmonised, comparable manner.
Amendment 97 #
Draft opinion
Paragraph 7 k (new)
Paragraph 7 k (new)
7 k. Calls on the Member States to ensure that all main stakeholders of the healthcare supply chain (manufacturers, full-service healthcare distributors /pharmaceutical full-line wholesalers, pharmacists) to be recognised as critical infrastructure to maintain the continuous and safe supply of medicines in extraordinary circumstances, such as the ones currently experienced in the COVID- 19 crisis or even taking into account the distribution of an upcoming vaccine.
Amendment 98 #
Draft opinion
Paragraph 7 l (new)
Paragraph 7 l (new)
7 l. Notes that the COVID-19 outbreak has laid bare the weaknesses of the European production system, highlighting the importance of delivering medicines swiftly in urgent and exceptional circumstances that could arise in the future, thereby stressing the importance and availability of existing and established infrastructure, including logistical hubs, warehouses and networks, for the safe and efficient distribution of medical supplies, including also the possibility for keeping stocks of medicines for emergency use.